Tonix Pharmaceuticals Holding Corp. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Tonix reported Q2 2026 TONMYA net revenue of $11.0 million (197% QoQ growth); total product revenue $13.5 million vs. $2.0 million YoY. Payer coverage expanded to 136 million lives (43% of U.S.). Cash declined from $207.6M (Dec 2025) to $176.2M (Jun 2026); operating cash burn was $84.6M for H1 2026 vs. $31.4M in H1 2025. First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for MDD; TNX-4800 Phase 2 for Lyme disease expected Q1 2027. Net loss $40.6M in Q2 2026 vs. $28.3M in Q2 2025; 17.2M shares outstanding as of Aug 7, 2026.
Why this rating
Strong TONMYA launch momentum and expanded payer coverage are positive, but Q2 burn rate ($84.6M H1) implies ~2-year runway at current pace relative to $176.2M cash—material execution risk. Pipeline progress is routine. Event is moderate-to-significant relative to $271M market cap.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.